As per the recently published report by MarketsandMarkets™, The report "HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region - Global Forecast to 2028", is projected to reach USD 2.1 billion by 2028 from an estimated value of USD 1.4 billion in 2022, at a CAGR of 6.5% during the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39129877

Browse
• 180 Market Data Tables
• 37 Figures
• 223 Pages and in-depth TOC on " HLA Typing Market - Global Forecast to 2028”

Some of the prominent key players are:
• Bio-Rad Laboratories, Inc. (US),
• F. Hoffmann-La Roche Ltd. (Switzerland),
• QIAGEN N.V. (Netherlands),
• Thermo Fisher Scientific Inc. (US),
• bioMérieux S.A. (France) and many more......
Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the HLA Typing Market.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=39129877
• Based on technology, the HLA typing market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest market share in 2022.
• Molecular assay techniques are used in HLA typing for applications such as donor-recipient cross-matching, cancer and autoimmune disease diagnostics, infectious disease diagnostics, and transfusion.
• Based on application, the diagnostic applications market is segmented into donor-recipient match, Cancer Diagnosis and prevention, Infectious and non-infectious disease testing, Transfusion Therapy and Others. The diagnostic applications segment accounted for the highest CAGR of 6.5% during the forecast period.
• Based on the region, the HLA Typing Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America accounted for the largest share of the HLA Typing Market.

Recent Developments:
• In March 2023, BioRad received The company received AOAC International and AFNOR approval for its iQ-Check kits, which are used with the CFX Opus Deepwell Real-time PCR System
• In August 2022 Roche developed a new digital Light cycler system that helps determine a patient’s cancer.
• In May 2022, CareDx received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT software. These AlloSeq are used in patients who have received Hematopoietic cell transplantation.